Dr. Naval Daver, an AML specialist, reviews genetic testing, how the results affect AML treatment decisions, and when retesting may be appropriate for patients.
Dr. Naval Daver is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. Learn more about Dr. Daver: [ Ссылка ].
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome.
Subscribe now to receive the latest news on cancer treatment and research: powerfulpatients.org/connect
Should AML Molecular Tests Be Repeated?
Теги
Acute Myeloid LeukemiaAMLAML treatmentDr. Naval Daveracute leukemia treatmentleukemia factsclinical trialsmolecular profilinggenetic testingMolecular TestingFLT3 InhibitorsmidostaurinrydaptgilteritinibxospatasorafenibnexavarIDH InhibitorsenasidenibidhifaivosidenibtibsovoBCL-2 inhibitorsvenclextavenetoclaxMLL RearrangementFLT3IDH1IDH2NPM1MLLASXL1RUNX1FDAhematologyblood cancergene mutations